Hatchtech Pty Ltd is a specialty pharmaceutical company co-located in Australia and the USA. The Company develops DeOvo™, a proprietary next generation head lice treatment that needs only a single application to provide clearance of an infestation. This property is in marked contrast to available anti-lice treatments that regularly need several applications to clear an infestation and is due to the fact that DeOvo™, kills the eggs as well as the adult lice ensuring one treatment is enough. Most other treatments cannot kill the eggs effectively. In addition, while head lice worldwide have developed resistance to many of the available products there is no known cross resistance with DeOvo™ as it has a totally novel mode of action.
DeOvo™ is a cosmetically elegant topical lotion containing an inhibitor of metalloproteases known to impede all stages of the louse lifecycle from egg to adult. A substantial body of scientific data has established the mode of action and preclinical and clinical studies have shown DeOvo™ to be both highly effective and safe.
DeOvo™ recently successfully completed a Phase IIb clinical trial confirming the product was both safe and highly effective following a single application. Hatchtech now plans to mount a Phase III clinical trial as soon as possible.
The Company was originally founded through programmes that originated at the University of Melbourne in Australia. Hatchtech has a comprehensive patent estate for DeOvo™ including both granted and pending patent applications.
Hatchtech is securely financed by a consortium of specialist venture capitalists.
Mar 12, 2013 Hatchtech appoints Hugh Alsop as CEO